The specter of generic competition has repeatedly loomed over copyright’s iconic drug, PDE5 Inhibitor, raising questions about the prospects of connected drug investments. While initial times saw significant profits, the exclusivity lapse has created the door for less expensive alternatives, likely lowering profitability and creating a significan